Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Pharmacogenomics Journal

• Publication date

  2014-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/tpj.2014.13PMID 24732178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy

  2013cited by this paper
• Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

  2013cited by this paper
• Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung

  2013cited by this paper
• Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

  2012cited by this paper
• Pharmacogenomics Knowledge for Personalized Medicine

  2012cited by this paper
• zCall: a rare variant caller for array-based genotyping: Genetics and population analysis

  2012cited by this paper
• The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy

  2010cited by this paper
• A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma

  2010cited by this paper
• Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study

  2010cited by this paper
• Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

  2010cited by this paper
• DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia

  2009cited by this paper
• The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate Carrier

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• PLINK: a tool set for whole-genome association and population-based linkage analyses.

  2007cited by this paper
• Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications

  2007cited by this paper
• Population Structure and Eigenanalysis

  2006cited by this paper
• Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.

  2006cited by this paper
• Principal components analysis corrects for stratification in genome-wide association studies

  2006cited by this paper
• Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.

  2005cited by this paper
• Lack of Impact of the Loss of Constitutive Folate Receptor α Expression, Achieved by RNA Interference, on the Activity of the New Generation Antifolate Pemetrexed in HeLa Cells

  2004cited by this paper
• A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.

  2004cited by this paper
• Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.

  2003cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

  2002cited by this paper
• Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesothelioma.

  2002cited by this paper
• Thymidylate synthase inhibitors.

  2001cited by this paper
• Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

  1999cited by this paper
• Glutamyl hydrolase and the multitargeted antifolate LY231514

  1999cited by this paper
• LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

  1997cited by this paper
• Thymidylate synthase inhibitors.

  1996cited by this paper
• Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.

  1995cited by this paper
• Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.

  1995cited by this paper
• Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity.

  1994cited by this paper
• A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.

  1992cited by this paper

• Efficacy and Safety of Genetic Testing-Guided Chemotherapy vs. Empiric Chemotherapy in Patients with Advanced Lung Cancer

  2025cites this paper
• Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review

  2024cites this paper
• Identification of molecular biomarkers associated with non-small-cell lung carcinoma (NSCLC) using whole-exome sequencing

  2023cites this paper
• Effect of ADME gene polymorphisms on pemetrexed pharmacokinetics in patients with non-small-cell lung cancer: A prospective study

  2022cites this paper
• SLC19A1 and Thymidylate Synthase Polymorphisms do not Predict Survival Outcome in Non-Small-Cell Lung Cancer Treated with Pemetrexed-Cisplatin Chemotherapy Regimen

  2022cites this paper
• Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China

  2021cites this paper
• Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer

  2021cites this paper
• MTHFR polymorphism as a predictive biomarker for gastrointestinal and hematological toxicity in North Indian adenocarcinoma patients

  2021cites this paper
• Identi�cation of Molecular Biomarkers Associated with Non-Small-Cell Lung Carcinoma (NSCLC) Using Whole-Exome Sequencing Analysis

  2021cites this paper
• PGPM_A_327313 1647..1660

  2021cites this paper
• Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China

  2021cites this paper
• Systematic review and meta-analysis of the predictive power of MTHFR polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients

  2021cites this paper
• Impact of genetic factors on platinum-induced gastrointestinal toxicity.

  2020cites this paper
• Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

  2019cites this paper
• Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study

  2019cites this paper
• The genetic landscape of the human solute carrier (SLC) transporter superfamily

  2019cites this paper
• Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients

  2019influential citation
• GUNA LOW DOSE CYTOKINES: A MODERN APPROACH IN RHEUMATOLOGY WITH PROVED EFFICACY AND SAFETY

  2018cites this paper
• Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS)

  2018cites this paper
• Statistical assessment of repeated measures data with application in oncology

  2017influential citation
• Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.

  2017cites this paper
• Mutations in folate transporter genes and risk for human myelomeningocele

  2017cites this paper
• Whole exomes sequencing for neurofibromatosis type I patients complicated with gastrointestinal stromal tumors

  2016cites this paper
• Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.

  2016cites this paper
• An angiotensin‐converting enzyme (ACE) polymorphism may mitigate the effects of angiotensin‐pathway medications on posttraumatic stress symptoms

  2015cites this paper